The direct trial (daily-dose consensus interferon and ribavirin: efficacy of combined therapy): Treatment of non-responders to previous pegylated interferon plus ribavirin: Sustained virologic response data

被引：0
|
作者：
Bacon, Bruce
Regev, Arie
Ghalib, Reem H.
Morelli, Giuseppe
Rothstein, Kenneth D.
Shiffman, Mitchell L.
Hossanein, Tarek
Hammond, Janet
机构：
[1] St Louis Univ, Sch Med, Liver Ctr, St Louis, MO 63103 USA
[2] Univ Miami, Coral Gables, FL 33124 USA
[3] Methodist Hosp, Liver Inst, Dallas, TX USA
[4] Univ Florida, Gainesville, FL 32611 USA
[5] Albert Einstein Ctr Liver Dis, Philadelphia, PA USA
[6] Virginia Commonwealth Univ, Richmond, VA 23284 USA
[7] Univ Calif San Diego, La Jolla, CA 92093 USA
[8] Valeant Pharmaceut N Amer, Aliso Viejo, CA USA
来源：
HEPATOLOGY | 2007年 / 46卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
168
引用
收藏
页码：311A / 312A
页数：2
相关论文
共 50 条
  • [31] Efficacy of the treatment with interferon, ribavirin and amantadine, in patients with hepatitis C non-responders or relapsers to the conventional therapy.
    Carmen, SE
    HEPATOLOGY, 2002, 36 (04) : 588A - 588A
  • [32] Sustained virologic response rates with Albumin interferon alfa-2b in combination with ribavirin in non-responders to prior interferon therapy: Interim results from a Phase 2 study
    Nelson, David
    Rustgi, Vinod
    Balan, Vijayan
    Sulkowski, Mark
    McHutchison, John
    Davis, Gary L.
    Lambiase, Louis
    Dickson, Rolland
    Yu, Ren
    Novello, Lu Anne
    Freimuth, William
    Subramanian, Mani
    HEPATOLOGY, 2006, 44 (04) : 611A - 612A
  • [33] Predictive value of early HCV RNA quantification for sustained response in non responders receiving daily interferon and ribavirin therapy
    Trimoulet, P
    de Ledinghen, V
    Foucher, J
    Castera, L
    Fleury, H
    Couzigou, P
    JOURNAL OF HEPATOLOGY, 2003, 38 : 177 - 177
  • [34] LINICAL EFFICACY/EFFECTIVENESS OF COMBINED THERAPY WITH INTERFERON (PEGYLATED OR NON-PEGYLATED) plus RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C
    Almadiyeva, A.
    Kostyuk, A.
    VALUE IN HEALTH, 2013, 16 (03) : A81 - A81
  • [35] Interferon alpha-2B/ribavirin in both high and standard dose induces sustained response in previous interferon monotherapy non-responders.
    Herrine, SK
    Weinberg, DS
    Greenfield, SM
    Shaw, EW
    Thornton, JJ
    HEPATOLOGY, 2000, 32 (04) : 353A - 353A
  • [36] EFFICACY AND SAFETY OF AN INTENSIFIED REGIMEN OF PEGYLATED INTERFERON ALFA-2A PLUS RIBAVIRIN IN HCV GENOTYPE 1 NON-RESPONDERS: AN INTERIM ANALYSIS OF THE SYREN TRIAL
    Hezode, C.
    Foucher, J.
    Bronowicki, J. -P.
    Leroy, V.
    Tran, A.
    Larrey, D.
    Mathurin, P.
    Rosa, I.
    Alric, L.
    Dhalluin-Venier, V.
    Nani, A.
    Bouvier-Alias, M.
    Rouanet, S.
    Couzigou, P.
    Mallat, A.
    Charaf-Eddine, M.
    Pawlotsky, J. -M.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S50 - S50
  • [37] African-American and Caucasian "non-responders" have similar biochemical and virologic response patterns to interferon plus ribavirin therapy for chronic HCV infection.
    Yee, LJ
    Langner, RG
    Kaslow, RA
    Van Leeuwen, D
    HEPATOLOGY, 2000, 32 (04) : 568A - 568A
  • [38] Efficacy of high dose consensus interferon for the treatment of chronic hepatitis C non responders to interferon alpha 2b and ribavirin.
    Moskovitz, DN
    Manoharan, P
    Heathcote, J
    HEPATOLOGY, 2001, 34 (04) : 577A - 577A
  • [39] A combined therapy with high dose of interferon (IFN)-alpha as an induction and ribavirin in non-responders to IFN alone with chronic hepatitis C
    Takashimizu, S
    Watanabe, N
    Mine, T
    Matsuzaki, S
    GASTROENTEROLOGY, 2003, 124 (04) : A781 - A781
  • [40] Comparison of Pegylated interferon plus ribavirin with or without induction therapy for the treatment of chronic hepatitis C (HCV) non-responders.
    Bzowej, N
    Gish, R
    Wakil, A
    Brooks, L
    Shaffer, M
    Leung, J
    HEPATOLOGY, 2002, 36 (04) : 577A - 577A
12345